RAPT Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 29.27 million compared to USD 20.47 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 0.69 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 USD | -2.42% | -6.70% | -83.74% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.74% | 141M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023